$121,795,918
to THE CRITICAL PATH INSTITUTE
CRITICAL PATH PUBLIC PRIVATE PARTNERSHIPS
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Funds the Critical Path Institute's public-private partnerships to accelerate FDA drug development and regulatory science initiatives.
Streamlines pharmaceutical approval pathways by bridging FDA, industry, and academia—reducing time-to-market for critical medicines and vaccines.
Strengthens coordination between pharmaceutical manufacturers, regulators, and research institutions on development standards and data sharing.
Enhances U.S. pharmaceutical innovation speed and regulatory efficiency to maintain competitive advantage in global drug development.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-26. Cost: $0.002860.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier ASST_NON_U18FD005320_075.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.